title: Disease modifying therapies in multiple sclerosis: could a baseline thyroid check-up drive the therapeutic choice between interferon-β and glatiramer acetate?
authors.affiliation: Unit of Internal Medicine and Endocrinology, Fondazione Salvatore Maugeri IRCCS, Chair of Endocrinology University of Pavia, Italy.
authors.forename: Mario
authors.initials: M
authors.lastname: Rotondi
authors.affiliation: Interdepartmental Research Centre for Multiple Sclerosis (CRISM), National Neurological Institute C Mondino, IRCCS, Pavia, Italy.
authors.forename: Roberto
authors.initials: R
authors.lastname: Bergamaschi
authors.affiliation: Unit of Internal Medicine and Endocrinology, Fondazione Salvatore Maugeri IRCCS, Chair of Endocrinology, University of Pavia, Via S Maugeri 10, Pavia, I-27100, Italy luca.chiovato@fsm.it.
authors.forename: Luca
authors.initials: L
authors.lastname: Chiovato
mesh_terms: D000068717:Glatiramer Acetate / Q000627:therapeutic use*; D006801:Humans; D016899:Interferon-beta / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology*; D013960:Thyroid Function Tests; D013961:Thyroid Gland / Q000187:drug effects / Q000503:physiopathology*
chemical_list: D000068717:Glatiramer Acetate; D016899:Interferon-beta